“…Furthermore, insulinotropic peptides, such as glucagon‐like peptide‐1 (GLP‐1), exendin‐4 (Ex‐4), or insulin‐like growth factor‐1 (IGF‐1), as well as proangiogenic factors and cells such as VEGF, platelet‐derived growth factor (PDGF), and endothelial cells (ECs), have been combined with these scaffolds and islets, in both in vitro (Kizilel et al, ; Lin & Anseth, ) and in vivo approaches (Brady et al, ; Farina et al, ; Hlavaty et al, ; Y. Li et al, ; Linn et al, ; Phelps, Headen, Taylor, Thulé, & García, ; Phelps, Templeman, Thulé & García, ), showing significant improvements in insulin secretion, islet survival, and engraftment. In other studies, immunosuppressive drugs (Haque, Jeong, & Byun, ; Pinto et al, ) or even immunomodulatory cells, such as regulatory T cells (Treg; Graham et al, ) or mesenchymal stem cells (MSCs; Borg et al, ; Gołąb et al, ; Marek et al, ), were combined with synthetic materials and used in vitro and in vivo to enhance their immunoprotective functions and subsequently prevent the immune reaction against nonautologous islets. Moreover, with the aim of “functionalizing” these synthetic scaffolds, that is, increasing their biocompatibility, they have been coupled with bioactive agents that increase the hydrophilicity of their surfaces (Liu, Holzwarth, & Ma, ).…”